Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings

Annals of Family Medicine

Volumn 5, Issue 2, 2007, Pages 146-150

  Mintzer, Ira L ^a,c   Eisenberg, Mark ^b   Terra, Maria ^a   MacVane, Casey ^b   Himmelstein, David U ^a   Woolhandler, Steffie ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CAMBRIDGE HOSPITAL   (United States)

Author keywords

Narcotic addiction drug therapy; Narcotic antagonists; Opiate addiction; Patient selection; Primary care issues; Primary health care; Research, practice based; Substance abuse

Indexed keywords

BUPRENORPHINE; NALOXONE;

ADULT; ARTICLE; CARDIOMYOPATHY; COHORT ANALYSIS; COMMUNITY CARE; CONTROLLED STUDY; DISRUPTIVE BEHAVIOR; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG URINE LEVEL; FEMALE; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PARAMETER; PRIMARY MEDICAL CARE; TREATMENT DURATION; TREATMENT OUTCOME; URBAN POPULATION; URINALYSIS;

ADULT; BUPRENORPHINE; COMMUNITY HEALTH SERVICES; DRUG COMBINATIONS; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MASSACHUSETTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; OUTPATIENT CLINICS, HOSPITAL; PRIMARY HEALTH CARE; SELF-HELP GROUPS; TREATMENT OUTCOME;

EID: 34047148797     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.665     Document Type: Article

References (15)

1. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60(1):39-50.
2. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750-2755.
3. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-958.
4. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003(2):CD002207.
5. Federal Financial Institutions Examination Council (FFIEC) Geocoding System. Available at: http://www.ffiec.gov/Geocode/Geocode-Searchmapping.
6. SAS System for Windows. Version 8e. Cary, NC: SAS Institute; 2005.
7. Johnson EE, Christie MJ, Connor M. The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment. Neurosignals. 2005;14(6):290-302.
8. O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100-105.
9. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038-1041.
10. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction. 2002;97(11):1395-1404.
11. Bridge TP, Fudala PJ, Herbert S, Leiderman DB. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 2003;70(Suppl 2):S79-S85.
12. Des Jarlais DC, Friedman SR, Sotheran JL, et al. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA. 1994;271(2):121-127.
13. Ghodse H, Oyefeso A, Kilpatrick B. Mortality of drug addicts in the United Kingdom 1967-1993. Int J Epidemiol. 1998;27(3):473-478.
14. Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137(8):688-692.
15. Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: reaching new patient populations. Am J Psychiatry. 2001;158(8):1200-1204.